Rapport Therapeutics, Inc. (NASDAQ:RAPP) has 140 institutional investors that have filed 13F reports for the period ending December 2025.
| Owner Name | Date | Shares Held | Change (QoQ) | Change (%) | Value (USD) |
|---|---|---|---|---|---|
| FMR LLC | 31 Mar, 2026 | 7,168,939 | 57,074 | 0.80% | $224,316,101.00 |
| TRV GP V, LLC | 31 Mar, 2026 | 7,135,233 | 0 | 0.00% | $223,261,441.00 |
| ARCH Venture Management, LLC | 31 Mar, 2026 | 3,728,738 | 0 | 0.00% | $116,672,212.00 |
| Capital International Investors | 31 Mar, 2026 | 3,097,973 | -304,556 | -8.95% | $96,935,575.00 |
| Cormorant Asset Management, LP | 31 Mar, 2026 | 2,957,521 | -70,000 | -2.31% | $92,540,832.00 |
| Goldman Sachs Group Inc | 31 Mar, 2026 | 2,942,251 | -3,061,507 | -50.99% | $92,063,034.00 |
| BlackRock, Inc. | 31 Mar, 2026 | 2,505,955 | 74,093 | 3.05% | $78,411,332.00 |
| Sofinnova Investments, Inc. | 31 Mar, 2026 | 1,904,408 | 0 | 0.00% | $59,588,926.00 |
| Johnson & Johnson | 31 Mar, 2026 | 1,784,517 | -1,784,517 | -50.00% | $55,837,537.00 |
| Polar Capital Holdings Plc | 31 Mar, 2026 | 1,642,461 | 637,733 | 63.47% | $51,392,605.00 |
| BAKER BROS. ADVISORS LP | 31 Mar, 2026 | 1,547,090 | 0 | 0.00% | $48,408,446.00 |
| Vestal Point Capital, LP | 31 Mar, 2026 | 1,436,229 | 326,229 | 29.39% | $44,939,605.00 |
| VANGUARD CAPITAL MANAGEMENT LLC | 31 Mar, 2026 | 1,325,082 | 1,325,082 | 0.00% | $41,461,816.00 |
| TRV GP VI, LLC | 31 Mar, 2026 | 969,218 | 0 | 0.00% | $30,326,831.00 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 31 Mar, 2026 | 918,866 | -33,505 | -3.52% | $28,751,317.00 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 31 Mar, 2026 | 866,456 | 866,456 | 0.00% | $27,112.00 |
| State Street Corp | 31 Mar, 2026 | 759,552 | 44,731 | 6.26% | $23,766,382.00 |
| ALLIANCEBERNSTEIN L.P. | 31 Mar, 2026 | 727,843 | -60,568 | -7.68% | $22,082,757.00 |
| GEODE CAPITAL MANAGEMENT, LLC | 31 Mar, 2026 | 721,622 | 26,888 | 3.87% | $22,583,176.00 |
| PERCEPTIVE ADVISORS LLC | 31 Mar, 2026 | 673,923 | 0 | 0.00% | $21,087,051.00 |